Neoleukin Therapeutics, Inc. — Q2 2021 Form 10-Q
Issuer note: The filing is for Neoleukin Therapeutics, Inc., not Neurogene Inc. It covers the quarter and six months ended June 30, 2021; financial statements are unaudited.
Business context
Neoleukin is a clinical-stage biopharmaceutical company developing immunotherapies using de novo protein design. NL-201, its lead candidate, is in a Phase 1 trial for advanced solid tumors. The company reported no product revenue and has not achieved profitability.
Key financial metrics
| Metric | Q2 2021 | Q2 2020 | Six months 2021 | Six months 2020 |
|---|---|---|---|---|
| Research and development expense | $9.8 million | $4.8 million | $19.5 million | $10.3 million |
| General and administrative expense | $5.3 million | $4.9 million | $10.6 million | $8.5 million |
| Total operating expenses | $15.1 million | $9.8 million | $30.1 million | $18.8 million |
| Net loss | $15.1 million | $9.7 million | $30.1 million | $18.4 million |
| Basic and diluted net loss per share | $0.27 | $0.20 | $0.55 | $0.37 |
- Cash and liquidity: Cash and cash equivalents were $164.2 million at June 30, 2021, down from $192.6 million at December 31, 2020. Including $0.9 million of restricted cash, total cash, cash equivalents and restricted cash were $165.1 million. Management reported working capital of $159.9 million.
- Cash flow: For the first six months, operating cash use was $26.6 million, investing cash use was $2.3 million, and financing provided $0.6 million. Cash, cash equivalents and restricted cash decreased $28.3 million.
- Debt and obligations: The balance sheet reports no conventional borrowings. Total liabilities were $20.0 million, primarily operating lease liabilities; current and non-current operating lease liabilities totaled $13.4 million. The March 2021 lease amendment increased future operating lease payments through 2026 by $1.9 million.
- Margins: Revenue and profit margins are not meaningful because the company had no product revenue and recorded a net loss.
Material changes versus prior comparable periods
- Q2 operating expenses rose 55% year over year; first-half operating expenses rose 60%. R&D growth primarily reflected NL-201 IND-enabling and clinical-trial activity, other technology development, and the Seattle headquarters and laboratory build-out.
- First-half operating cash use increased from $15.2 million to $26.6 million, reflecting higher development and facility-related spending.
- Interest income declined substantially: $8,000 for the first half of 2021 versus $480,000 in 2020, primarily due to lower interest rates.
- Stock-based compensation expense increased to $5.3 million for the first half from $1.7 million a year earlier.
Outlook, commentary and risks
- Management expects existing cash and cash equivalents to fund planned operations into 2023. It also says substantial additional capital will be needed over time; financing may not be available on acceptable terms and could dilute shareholders or constrain operations.
- The first patient was dosed in the NL-201 Phase 1 trial in May 2021. The planned study may enroll up to 120 patients and evaluates safety, pharmacokinetics, pharmacodynamics, immunogenicity and antitumor activity. The filing provides no specific financial guidance.
- In June 2021, the company suspended plans to advance its NL-CVX1 COVID-19 research program into clinical trials, citing changes in the therapeutic landscape, including widespread availability of effective vaccines.
- Key risks include early-stage clinical and preclinical development, potential adverse events (including cytokine-related toxicity or immune reactions), trial delays or enrollment challenges, reliance on third-party manufacturers and research organizations, capital needs, and uncertainty around the company’s de novo protein platform. COVID-19 could also disrupt operations or development.
- The company said it was not party to legal proceedings expected by management to have a material adverse effect. Management concluded disclosure controls were effective at a reasonable-assurance level and reported no material change in internal control over financial reporting during the quarter.
Investor verification priorities
- Confirm the issuer identity: this source is Neoleukin Therapeutics, despite the request metadata naming Neurogene Inc.
- Track NL-201 Phase 1 safety, enrollment, dose escalation and timing of any indication-specific expansion cohorts.
- Assess cash burn against the stated runway into 2023, and monitor the timing, terms and dilution of any future financing.
- Reconcile the 42.4 million common shares outstanding at June 30 with 12.7 million pre-funded warrants and the reported weighted-average share count; assess potential dilution.
- Monitor R&D spending, Seattle facility costs and lease commitments, as well as any effects of the NL-CVX1 program suspension.